Venkatesh Brahma, MD
Ophthalmology · Santa Rosa, CANPI 1760877906
Payments from drug & device makers
Across 36 payments — averaging $26.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$395
- Alcon$201
- Biotissue Holdings Inc.$68
- Sun Pharmaceutical Industries Inc.$64
- Tarsus Pharmaceuticals, Inc.$61
- Bausch & Lomb Americas Inc.$50
- plus $127 from 6 others
What the payments were for
- Food & beverage$94898%
- Education$182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $395 |
| Alcon | 7 | $201 |
| Biotissue Holdings Inc. | 2 | $68 |
| Sun Pharmaceutical Industries Inc. | 3 | $64 |
| Tarsus Pharmaceuticals, Inc. | 3 | $61 |
| Bausch & Lomb Americas Inc. | 3 | $50 |
| Rayner Intraocular Lenses Limited | 1 | $33 |
| Dompe US, Inc. | 1 | $26 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Novartis | 1 | $12 |
How this compares
$966 in reported general payments places this provider in the 40th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $26,414 |
| Prednisolone Acetate | 318 | $16,429 |
| Cyclosporine | 15 | $6,785 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 100 | $3,790 |
| Latanoprost | 200 | $3,158 |
| Loteprednol Etabonate | 12 | $2,129 |
| Brimonidine Tartrate | 36 | $1,885 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 90 | $1,565 |
| Pyridostigmine Bromide | 32 | $1,471 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 128 | $1,293 |
| Timolol Maleate | 47 | $637 |
| Ketorolac Tromethamine | 22 | $409 |
| Prednisone | 39 | $383 |
| MoxifloxacinMoxifloxacin Hcl | 13 | $175 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Santa Rosa
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.